Aetna does cover genetic testing, but only when a physician documents that the test meets the insurer’s medical-necessity criteria and the patient fits the specific clinical rules Aetna sets for that condition. Tests that fall outside those rules, along with direct-to-consumer kits, general population screening, and most broad multi-gene panels, are classified as experimental or investigational and are not paid for. The details depend on the test, the diagnosis, and whether you have a commercial plan, a Medicaid managed care plan, or Medicare Advantage.
The Four Medical Necessity Requirements
Aetna’s main genetic testing policy, Clinical Policy Bulletin 0140, sets four conditions that must all be met.1Aetna. Genetic Testing You must either show clinical features of the condition or be at direct risk of inheriting it. The result of the test must directly affect a treatment decision. A definitive diagnosis must still be uncertain after a standard workup, including medical history, physical exam, family pedigree, genetic counseling, and conventional lab work. And you have to meet the disease-specific criteria Aetna has written for that particular condition.
If any one of those four is missing, the test is likely to come back as experimental, investigational, or unproven. Screening the general population for most genetic conditions sits in that excluded group, as does repeat testing for a condition already evaluated and any test ordered without a clear clinical reason.
Hereditary Cancer Testing
BRCA, Breast, and Ovarian Cancer
Aetna covers germline multigene panel testing for breast and ovarian cancer susceptibility genes once per lifetime for members who meet National Comprehensive Cancer Network criteria. The panel must include, at minimum, the high-penetrance breast cancer susceptibility genes. Panels that extend beyond the NCCN-recommended genes, or that include RNA analysis or polygenic risk scores, are not covered.2Aetna. Breast and Ovarian Cancer Susceptibility Gene Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy
Under the Affordable Care Act, most non-grandfathered plans must cover BRCA genetic counseling and testing with no out-of-pocket cost for women whose family history suggests an increased risk of harmful BRCA1 or BRCA2 mutations. The U.S. Preventive Services Task Force gives this a “B” rating, which triggers the ACA’s zero-cost-sharing rule, and insurers must defer to the attending provider’s clinical judgment on who qualifies.3U.S. Department of Labor. FAQs About Affordable Care Act Implementation Part 26 The ACA mandate does not reach men, genes beyond BRCA1 and BRCA2, or other hereditary cancer syndromes such as Lynch syndrome.4FORCE. Genetic Counseling and Testing Under the ACA
Access typically runs through a doctor trained in genetics or a certified genetic counselor, who decides whether testing is appropriate and submits a testing request form to Aetna.5Aetna. Breast and Ovarian Cancer
Lynch Syndrome and Other Inherited Cancer Syndromes
Germline testing for familial colorectal, endometrial, and gastric cancers is covered when the member meets NCCN criteria for specific syndromes, including Lynch syndrome, adenomatous polyposis, juvenile polyposis, Peutz-Jeghers syndrome, hereditary diffuse gastric cancer, and serrated polyposis syndrome. Multi-gene panels for these cancers are covered only when there is a personal or family history, more than one inherited syndrome could fit the picture, and the panel is more efficient than running individual tests one at a time. Like breast cancer panels, inherited cancer panel testing is a once-in-a-lifetime benefit.1Aetna. Genetic Testing
Prenatal and Carrier Screening
Carrier Screening
Expanded carrier screening is covered once per lifetime for people who are pregnant or planning a pregnancy. The panel must include cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, and a broad pan-ethnic panel covering at least 15 genes is covered for conditions with a carrier frequency of at least one in 200. Repeat carrier screening is not covered.1Aetna. Genetic Testing
For people of Ashkenazi Jewish ancestry, Aetna covers a targeted panel of 14 conditions, including Tay-Sachs disease, Canavan disease, cystic fibrosis, and familial dysautonomia. If only one partner has Ashkenazi Jewish ancestry, the second partner is tested only after the first partner’s result comes back positive.
Noninvasive Prenatal Testing
Noninvasive prenatal testing is covered for all pregnant women to screen for trisomies 13, 18, and 21 and sex chromosome aneuploidy. It is not covered if the patient has already had a negative multiple serum marker screening test during the same pregnancy. Using NIPT to screen for microdeletions, microduplications, rare autosomal trisomies, or single-gene conditions is classified as experimental and not covered.6Aetna. Noninvasive Down Syndrome Screening
Invasive Prenatal Diagnosis and Preimplantation Testing
Chorionic villus sampling, genetic amniocentesis, and cordocentesis are covered for diagnosing fetal chromosomal abnormalities. Conventional cytogenetic analysis and QF-PCR are covered when there is an increased risk of aneuploidy.7Aetna. Invasive Prenatal Diagnosis
Preimplantation genetic testing for monogenic disorders and structural rearrangements is covered only when both parents are confirmed carriers of the relevant mutation, the test will eliminate the need for a later invasive prenatal procedure, and the disease is associated with significant morbidity. Preimplantation testing for aneuploidy is classified as experimental for every indication, including recurrent miscarriage and advanced maternal age.
Pharmacogenomic Testing
Aetna covers pharmacogenomic tests tied to specific drugs when a patient meets the clinical criteria for that drug.8Aetna. Pharmacogenetic and Pharmacodynamic Testing In oncology, that includes biomarker testing for ALK, BRAF, somatic BRCA, EGFR, HER2, KRAS, PD-L1, and NTRK fusions, among others. Outside cancer, covered tests include CFTR mutation testing for cystic fibrosis drug eligibility, CYP2C19 genotyping for clopidogrel, CYP2D6 genotyping for tetrabenazine, and HLA genotyping to screen for hypersensitivity to drugs such as carbamazepine, allopurinol, and abacavir.
Broad multi-gene pharmacogenomic panels are a different matter. Products including GeneSight, Genomind, and the RightMed panels are classified as experimental and not covered. The same applies to MTHFR genotyping for antidepressant guidance and CYP450 testing for warfarin dosing. Large commercial tumor panels such as FoundationOne CDx and Guardant360 CDx are listed as not medically necessary for several specific cancer indications, with Aetna citing no proven advantage over targeted testing.
Whole Exome and Whole Genome Sequencing
Whole exome and whole genome sequencing are covered when a genetic cause is the most likely explanation for the patient’s condition and targeted testing has failed to produce a diagnosis. Qualifying situations include two or more congenital abnormalities in unrelated organ systems, unexplained developmental regression, complex neurodevelopmental disorders, and bilateral sensorineural hearing loss that targeted panels have not explained.9Aetna. Whole Exome Sequencing Precertification Form
The threshold is high. Alternate explanations must be ruled out, the clinical picture must not fit a well-described syndrome with available targeted testing, and the ordering provider must show that the test will change health outcomes. A pre-test consultation by an independent genetics professional is required, and both pre- and post-test counseling must be part of the care plan.
Genetic Counseling
Counseling is covered as a separate benefit when it accompanies pregnancy management or medically necessary genetic testing. Covered pregnancy indications include consanguinity, familial cancer disorders, membership in ethnic groups at higher risk for specific conditions, parental chromosomal abnormalities, and a history of stillbirth or repeated miscarriage. Outside pregnancy, counseling is covered when it accompanies or prepares for medically necessary testing in line with American College of Medical Genetics guidelines.10Aetna. Genetic Counseling For BRCA testing, Aetna treats counseling as essential before any test is ordered, covering risk status, potential outcomes, benefits and limitations, therapeutic options, and possible psychological effects.2Aetna. Breast and Ovarian Cancer Susceptibility Gene Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy
What Aetna Will Not Cover
Several categories sit outside coverage no matter who orders them. Direct-to-consumer genetic tests and general population screening for most conditions are excluded, because they fail the clinical-context requirement of a symptom or direct risk. Multi-gene pharmacogenomic panels used to guide psychiatric medication are experimental. Tumor chemosensitivity assays, which attempt to predict which chemotherapy a cancer will respond to, are also classified as experimental, consistent with the position of the American Society of Clinical Oncology.11Aetna. Tumor Chemosensitivity Assays Polygenic risk scores, RNA analysis in cancer panels, preimplantation testing for aneuploidy, and NIPT for microdeletions all land in the experimental category. Testing people under 18 for BRCA mutations is not considered medically necessary, and repeat testing for the same condition is generally excluded.
Prior Authorization
Many genetic tests need prior authorization before the lab runs them. BRCA and breast/ovarian susceptibility testing requires the provider to complete a specific Aetna form, submit it with the lab’s requisition, and wait for precertification; providers can request the form by calling 877-794-8720.2Aetna. Breast and Ovarian Cancer Susceptibility Gene Testing, Prophylactic Mastectomy, and Prophylactic Oophorectomy Aetna’s 2026 precertification list also requires prior authorization for whole exome sequencing, whole genome sequencing, and preimplantation genetic testing.12Aetna. Aetna Participating Provider Precertification List For Aetna Better Health Medicaid managed care plans, all genetic testing requires prior authorization, and the ordering provider is responsible for submitting the request.13Aetna Better Health. Genetic Testing Prior Authorization Requirements
If You Have Medicare Advantage
Aetna Medicare Advantage plans follow CMS National Coverage Determinations, not Aetna’s commercial policies. For next-generation sequencing in cancer, CMS covers testing for patients with advanced cancer (recurrent, relapsed, refractory, metastatic, or stage III–IV) who have decided to pursue further treatment. The test must be FDA-approved or cleared as a companion diagnostic for the patient’s cancer type, ordered by the treating physician, and run in a CLIA-certified lab.14CMS. Next Generation Sequencing NCD 90.2 In 2020, CMS extended NGS coverage to patients with breast or ovarian cancer who have a clinical indication and a risk factor for hereditary cancer, with the same FDA and CLIA requirements. Medicare Administrative Contractors have some discretion to cover NGS in scenarios the national determination does not address directly.15Aetna. Medicare Coverage Determinations
If a Test Is Denied
You have 180 days from the date of the denial notice to file an appeal. Appeals can be submitted by phone through Member Services or in writing using Aetna’s complaint and appeal form. Supporting documentation from the ordering physician, especially evidence that you meet the specific criteria in Aetna’s clinical policy or represent an exceptional clinical case, strengthens the appeal.16Aetna. Claim Denials
Depending on the plan, Aetna uses either a one-level or two-level appeal process. For standard pre-service claims, one-level plans issue a decision within 30 days; two-level plans respond within 15 days at the first level. Expedited appeals, available when a physician determines a delay could pose a serious health risk, are decided within 72 hours in one-level plans and 36 hours in two-level plans. Once internal appeals are exhausted, the ACA entitles you to request an external review by an independent third party.
The denials people see most often read as “not medically necessary,” “experimental or investigational,” or “not a covered benefit.” Appeals of “not medically necessary” denials tend to have better success rates than appeals of experimental classifications, particularly when the provider can show the patient meets Aetna’s written criteria or presents an exceptional clinical case.17ADLM. How to Successfully Navigate the Insurance Denial Appeal Process for Genetic Tests